CTLA4 and urinary bladder carcinoma: Anti-CTLA-4 can drive increased ICOS expression on T cells in clinical trials [33, 34], and ICOS upregulation on peripheral T cells is correlated with clinical responses to anti-CTLA-4 in bladder cancer [34].